ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

GILD Gilead Sciences Inc

65.09
-0.42 (-0.64%)
After Hours
Last Updated: 22:50:23
Delayed by 15 minutes
Share Name Share Symbol Market Type
Gilead Sciences Inc NASDAQ:GILD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.42 -0.64% 65.09 65.09 65.22 65.80 64.89 65.75 5,569,312 22:50:23

New Leadership for Gilead Sciences Canada, Inc. - Melissa Koomey Appointed Vice President and General Manager

05/03/2020 2:00pm

PR Newswire (Canada)


Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Gilead Sciences Charts.

MISSISSAUGA, ON, March 5, 2020 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada), based in Mississauga, Ontario, today announced the appointment of Melissa Koomey as Vice President and General Manager. Koomey will be responsible for leading Gilead Sciences' team across Canada.

"We are pleased to welcome Melissa as our new Vice President and General Manager for Canada operations," said Rudolf Ertl, Senior Vice President, Commercial Operations, Australia/Canada/Europe. "Over her more than seven years with Gilead, Melissa has served in many leadership roles, most recently as Vice President of the HIV Business Unit in the United States, making Melissa an exceptional leader for our Canadian business."

Prior to her time at Gilead Sciences, Koomey held leadership positions across therapeutic areas with several innovative medicines companies. Koomey holds a Bachelor of Arts from Yale College and a Master of Business Administration from Harvard Business School. Koomey is also a member of the Board of Directors of the National AIDS Memorial in San Francisco, California.

"I'm honoured to have been selected to lead Gilead Canada," Koomey said, "Now is a critical time for pharma in Canada. As the landscape for innovative medicines companies is shifting, we aim to optimize patient access to innovative medicines in a sustainable manner."  

"Canada is such a critical market in Gilead's global operations, and I am very pleased that Melissa will steward this next phase for Gilead Canada," said Ertl. Koomey succeeds Kennet Brysting, now Gilead Sciences' VP, Global Commercial Strategy, HIV & Emerging Viruses, based on Foster City, California. "Our thanks go out to Kennet Brysting who made an important impact on the business in Canada during his tenure here," Ertl said.

About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead Sciences Canada, Inc. is the Canadian affiliate of Gilead Sciences, Inc., and was established in Mississauga, Ontario in 2006.

SOURCE Gilead Sciences, Inc.

Copyright 2020 Canada NewsWire

1 Year Gilead Sciences Chart

1 Year Gilead Sciences Chart

1 Month Gilead Sciences Chart

1 Month Gilead Sciences Chart

Your Recent History

Delayed Upgrade Clock